Abstract:Bromhexine (BR), guaiafenesin (GUF) and salbutamol (SAL) are formulated as Ventocough syrup® (with and without sugar), labeled to contain propyl paraben and sodium benzoate as inactive ingredients. They are used to make coughing more productive and easier. A crucial element and a major issue in the pharmaceutical industry is the control of organic related impurities to obtain safe and effective treatment. Guaiacol (GUL) is reported to be GUF related impurity that was proved to be extremely toxic (toxic rating class 5), and its use should be banned. In this work, In-Silico study and ADMET estimation were conducted to predict GUL pharmacokinetic properties and its toxicity profile. Additionally, two chromatographic methods were conducted to analyze the studied components along with GUF impurity in the presence of the labeled dosage form excipients. The In-Silico study assured that GUL has oral rat acute toxicity and it is considered to be skin sensitizer. On the other hand, the developed TLC- densitometeric method depended on using a mobile phase mixture of hexane: methylene chloride: triethylamine (5.0:6.0:0.3, by volume) as a developing system. UV-Scanning was performed immediately at 275 nm for SAL, GUF and GUL, while scanning at 310 nm was used for scanning BR. Linearity was established in the ranges of 0.25–4.0, 0.25–4.0, 0.5–8.0 and 0.1–1.6 μg/band for BR, SAL, GUF and GUL, respectively. In the developed HPLC method, separation was performed on X-Bridge® C 18 column (250 × 4.6 mm, 5 μm) using a solvent mixture of 0.05M disodium hydrogen phosphate pH 3 with aqueous phosphoric acid: methanol (containing 0.3%, v/v triethylamine) (40:60, v/v). Detection was done at 225 nm and separation was achieved within 10 min. Linearity was proved in the range of 2–50 μg/mL for the proposed drugs. Validation of the developed methods was done and all the calculated parameters were within the acceptable limits recommended by ICH guidelines. After that, methods were used to examine the potency of the selected marketed dosage forms and concentrations of all drugs were within the acceptable limits. Additionally, complete separation between the studied drugs and the additives were observed. The developed methods can be used during routine quality control analysis of the proposed drugs when the required issues concern on sensitivity, selectivity and analysis time.

Isolation and Identification of an Unknown Impurity Contained in Ambroxol Hydrochloride Glucose Injection

Separation and Characterization of the Polymerized Impurities in Oxacillin Sodium by 2D HPSEC and HPLC IT-TOF MS

Impurity Profile and Spectrum Characteristics of the Isomers in Cefamandole Nafate Using High- Performance Liquid Chromatography/high-Performance Size Exclusion Chromatography Tandem Ion Trap/time-of-flight Mass Spectrometry

Chemical Fingerprint for Identification and Quality Control of Saccharides in Danhong Injection Based on HPLC-ELSD with Chemometrics

Characterization of eight unknown impurities and analysis of their source in xinfujunsu and injection by liquid chromatography coupled with ion trap/time-of-flight mass spectrometry

Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography.

A Drug–Excipient Interaction Impurity of Bromhexine Hydrochloride Injection: Structure and Formation Mechanism Elucidation

Rapid Characterization of an Unknown Impurity in Bulk Drug Levofloxacin Carboxylic Acid by High Performance Liquid Chromatography/mass Spectrometry

Isolation, structural characterization and quality control strategy of an unknown process-related impurity in sugammadex sodium

Development of novel gradient RP-HPLC method for separation of dapagliflozin and its process-related impurities: insight into stability profile and degradation pathway, identification of degradants using LCMS

Stability-indicating HPTLC determination of ambroxol hydrochloride in bulk drug and pharmaceutical dosage form

Isolation, Characterization of a Potential Degradation Product of Aspirin and an HPLC Method for Quantitative Estimation of Its Impurities

Identification and Quality Control Strategy of Impurities in Zhengqing Fengtongning Injection

An innovative impurity profiling of esmolol hydrochloride injection using UPLC-MS based multiple mass defect filter, chemometrics and in-silico toxicity prediction

Separation and synthesis of DHTQ

Chromatographic analysis of triple cough therapy; bromhexine, guaiafenesin and salbutamol and pharmaceutical impurity: in-silico toxicity profile of drug impurity

Analysis of Ambroxol Hydrochloride and 3,5-Dibromo-anth-o-animobenzaldehyde by Liquid Chromatography

Determination of the contents and related substances in Ambroxol hydrochloride orallydisintegrating tablet by HPLC

A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)

Interference by metabolites and the corresponding troubleshooting during the LC-MS/MS bioanalysis of G004, a bromine-containing hypoglycemic agent

Separation and structural characterization of unknown impurity in vancomycin by two-dimensional preparative liquid chromatography, LC-MS and NMR